Gilead Sciences, Inc. (GILD) 은(는) 상장 기업입니다 헬스케어 섹터의 제약 산업에서 운영. 본사 소재지는 Foster City, CA, 미국. 현재 CEO는 Daniel O'Day.
GILD 을(를) 보유 IPO 날짜 1992-01-22, 17,600 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $174.33B.
Gilead Sciences, Inc. is a biopharmaceutical company headquartered in Foster City, California, that discovers, develops, and commercializes innovative medicines addressing unmet medical needs across the United States, Europe, and international markets. The company's portfolio spans multiple therapeutic areas, including HIV/AIDS treatment with leading antiretroviral products such as Biktarvy and Truvada, hepatitis C and liver disease management through Epclusa and Harvoni, oncology and cell therapy with products like Yescarta and Trodelvy, and other critical care areas including pulmonary arterial hypertension and serious fungal infections. Gilead also gained prominence for Veklury, its antiviral treatment for COVID-19. The company maintains strategic collaboration agreements with numerous leading biopharmaceutical and research organizations to advance its pipeline and expand its therapeutic capabilities.
